MedPath

Sideritis Supplementation, Oxidative Stress and Health

Not Applicable
Completed
Conditions
Oxidative Stress
Lipidemia
Interventions
Dietary Supplement: Placebo supplementation
Dietary Supplement: Sideritis Scardica (SidTea+) extract supplementation
Registration Number
NCT05729659
Lead Sponsor
University of Thessaly
Brief Summary

The aim of the present clinical study is to estimate the efficacy of a Sideritis Scardica extract (SidTea+), derived from the Greek mountain Taygetos, in regulating antioxidant and health biomarkers in healthy adults.

Detailed Description

Introduction: The mountain tea of genus Sideritis has more than 150 species, which are mainly distributed in the Mediterranean area. In the literature, extensive reference is made to the secondary metabolites of Sideritis, the main ones of which are terpenoids (i.e., iridoids and kauranes) and phenolic derivatives (i.e., flavonoids, phenolic acids, phenylethanoid glycosides). Polyphenols exhibit a wide range of biological activities, such as anti-atherogenic, anti-cancer, anti-mutagenic, anti-inflammatory and antimicrobial properties. Among phenolic derivatives, major significance is given to flavonoids, due to their antioxidant, anti-inflammatory, antibacterial, antiviral and anti-allergic properties in various pathologies. Flavonoids mainly act as antioxidants, inhibiting free radical-induced cytotoxicity and lipid peroxidation. Moreover, these compounds are known to inhibit tumor growth and proliferation and act as weak agonists or antagonists of estrogens by regulating endogenous hormonal activity. In these ways, they can protect against chronic diseases such as atherosclerosis and cancer and regulate menopausal symptoms.

Purpose: This study aims to investigate the effect of a Sideritis Scardica extract (SidTea+) supplement from the Greek mountain Taygetos on health and oxidative stress indicators in healthy individuals. The results of the present investigation will help to elucidate the effects of an extract derived from a plant product on markers of health and oxidative stress in apparently healthy individuals.

Methodology: 30 healthy individuals will be enrolled in the study. Participants will give their informed consent after they will be informed about the purposes, procedures, risks and benefits associated with the study. Participants will be randomly allocated to either a Sideritis spp or a placebo supplementation group and they will consume 1500 mg/day of Sideritis or placebo, distributed in three equal doses (every 8 hours) for one month. At baseline and post-intervention, volunteers will be assessed for their anthropometric profile, muscle function and cardiorespiratory capacity and will provide a resting blood sample for the assessment of oxidative stress and health biomarkers. Participants will be asked to record their diet for 3 days prior to the study and they will be asked to follow the same dietary pattern for 3 days before the post-intervention assessments.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Healthy Individuals aged 18-65 years
Exclusion Criteria
  • Musculoskeletal injury
  • Dietary supplements
  • Medication

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo supplementationPlacebo will be administered to participants in this arm.
Sideritis Scardica (SidTea+) extractSideritis Scardica (SidTea+) extract supplementationSideritis Scardica (SidTea+) extract will be administered to participants in this arm.
Primary Outcome Measures
NameTimeMethod
Change in catalase activityChange from baseline to 1 month

Catalase activity will be analyzed in erythrocytes

Change in thiobarbituric acid reactive substances concentrationChange from baseline to 1 month

Thiobarbituric acid reactive substances concentration will be analyzed in plasma

Change in cholesterol concentrationChange from baseline to 1 month

Cholesterol concentration will be analyzed in plasma

Change in triglycerides concentrationChange from baseline to 1 month

triglycerides concentration will be analyzed in plasma

Change in high-density lipoprotein concentrationChange from baseline to 1 month

High-density lipoprotein concentration will be analyzed in plasma

Change in bilirubin concentrationChange from baseline to 1 month

Bilirubin concentration will be analyzed in plasma

Change in glutathione concentrationChange from baseline to 1 month

Glutathione concentration will be analyzed in erythrocytes

Change in total antioxidant capacityChange from baseline to 1 month

Total antioxidant capacity will be analyzed in serum

Change in protein carbonyls concentrationChange from baseline to 1 month

Protein carbonyls will be analyzed in plasma

Change in glucose concentrationChange from baseline to 1 month

Glucose concentration will be analyzed in plasma

Change in lactate dehydrogenase concentrationChange from baseline to 1 month

Lactate dehydrogenase concentration will be analyzed in plasma

Change in serum glutamic-oxaloacetic transaminase concentrationChange from baseline to 1 month

Serum glutamic-oxaloacetic transaminase will be analyzed in serum

Change in gamma-glutamyl transpeptidase concentrationChange from baseline to 1 month

Gamma-glutamyl transpeptidase concentration will be analyzed in serum

Change in creatinine concentrationChange from baseline to 1 month

Creatinine concentration will be analyzed in serum

Change in uric acid concentrationChange from baseline to 1 month

Uric acid concentration will be analyzed in serum

Secondary Outcome Measures
NameTimeMethod
Change in diastolic and systolic blood pressureChange from baseline to 1 month

Diastolic and systolic blood pressure will be measured using a manual sphygmomanometer

Change in handgrip strengthChange from baseline to 1 month

Handgrip strength will be measured using a hand dynamometer

Change in estimated maximal oxygen consumption (eVO2max)Change from baseline to 1 month

eVO2max will be measured using an automated open-circuit spirometer

Change in body weightChange from baseline to 1 month

Body weight will be measured using a digital scale

Change in body fatChange from baseline to 1 month

Body fat will be measured by bioelectrical impedance analysis

Change in resting heart rateChange from baseline to 1 month

Resting heart rate will be measured using a heart rate sensor

Dietary macro-nutrient analysisBaseline

Protein, carbohydrate and fat dietary intake will be measured using diet recalls (food questionnaires)

Change in waist and hip circumferenceChange from baseline to 1 month

Waist and hip circumference will be assessed using a tape measure

Change in complete blood countChange from baseline to 1 month

White blood cells, lymphocytes, monocytes, granulocytes, red blood cells and platelets will be analyzed in whole blood using an automated blood chemistry analyzer

Dietary micro-nutrient analysisBaseline

Vitamin C, vitamin E, zinc, methionine and cysteine dietary intake will be analyzed using diet recalls (food questionnaires)

Physical activity levelBaseline

Low, moderate and vigorous physical activity will be assessed by questionnaires

Trial Locations

Locations (1)

Exercise Biochemistry, Physiology and Nutrition Laboratory, Department of Physical Education and Sport Science, University of Thessaly

🇬🇷

Trikala, Thessaly, Greece

© Copyright 2025. All Rights Reserved by MedPath